Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Depreciation and Depletion (2016 - 2023)

Ekso Bionics Holdings (EKSO) has disclosed Depreciation and Depletion for 11 consecutive years, with $414000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Depreciation and Depletion rose 79.22% to $414000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $669000.0, a 0.45% change, with the full-year FY2025 number at $563000.0, down 14.44% from a year prior.
  • Depreciation and Depletion was $414000.0 for Q1 2023 at Ekso Bionics Holdings, up from -$146000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $414000.0 in Q1 2023 to a low of -$221000.0 in Q4 2021.
  • A 5-year average of $163000.0 and a median of $170000.0 in 2022 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 457.69% in 2020, then tumbled 242.58% in 2021.
  • Ekso Bionics Holdings' Depreciation and Depletion stood at $171000.0 in 2019, then dropped by 9.36% to $155000.0 in 2020, then crashed by 242.58% to -$221000.0 in 2021, then surged by 33.94% to -$146000.0 in 2022, then surged by 383.56% to $414000.0 in 2023.
  • Per Business Quant, the three most recent readings for EKSO's Depreciation and Depletion are $414000.0 (Q1 2023), -$146000.0 (Q4 2022), and $170000.0 (Q3 2022).